NO131549B - - Google Patents

Download PDF

Info

Publication number
NO131549B
NO131549B NO1613/71A NO161371A NO131549B NO 131549 B NO131549 B NO 131549B NO 1613/71 A NO1613/71 A NO 1613/71A NO 161371 A NO161371 A NO 161371A NO 131549 B NO131549 B NO 131549B
Authority
NO
Norway
Prior art keywords
axenomycin
culture medium
liter
culture
medium
Prior art date
Application number
NO1613/71A
Other languages
Norwegian (no)
Other versions
NO131549C (en
Inventor
E Cotta
P Julita
A Sanfilippo
Original Assignee
Farmaceutici Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutici Italia filed Critical Farmaceutici Italia
Publication of NO131549B publication Critical patent/NO131549B/no
Publication of NO131549C publication Critical patent/NO131549C/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06Fungi, e.g. yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

Fremgangsmåte ved fremstilling av et nytt Procedure for making a new one

antibiotikum, axenomycin D. antibiotic, axenomycin D.

Foreliggende oppfinnelse angår en fremgangsmåte ved fremstilling av et nytt antibiotikum. Oppfinnelsen er en videreut-vikling av norsk patentskrift 127.927 som.beskriver det antibiotiske kompleks axenomycin, de antibiotiske forbindelser axenomycin A The present invention relates to a method for the production of a new antibiotic. The invention is a further development of Norwegian patent document 127,927 which describes the antibiotic complex axenomycin, the antibiotic compounds axenomycin A

og axenomycin B og fremstilling.av disse ved dyrkning av Streptomyces lisandri under aerobe forhold. and axenomycin B and production of these by cultivating Streptomyces lysandri under aerobic conditions.

Ifolge foreliggende oppfinnelse er det nu funnet at According to the present invention, it has now been found that

ved dyrkning av Streptomyces lisandri under bestemte forhold erhol-des der et nytt antibiotikum kalt axenomycin D som har sterk tera-peutisk aktivitet. by cultivating Streptomyces lysandri under specific conditions, a new antibiotic called axenomycin D is obtained which has strong therapeutic activity.

Fremgangsmåten ifolge oppfinnelsen som omfatter dyrkning av en stamme av Streptomyces lisandri ved en temperatur fra 23 til 37°C i 60 - 160 timer ved en pH fra 6 til 9 i et vandig dyrkningsmedium inneholdende en assimilerbar nitrogenkilde, en assimilerbar carbonkilde og mineralsalter, og isoleringen ved opplosningsmiddel-ekstraksjon og kromatograf ering, er kjennetegnet ved at der anvendes et dyrkningsmedium hvis carbonkildeinnhold er lik eller storre enn 10 %, og at dyrkningen utfores ved omroring tilsvarende en absorbert kraft på 2 - 4 watt pr. liter, og med en luftstrom på fra 0,7 ti 1 2 liter pr. liter medium pr. minutt. The method according to the invention which comprises growing a strain of Streptomyces lysandri at a temperature from 23 to 37°C for 60 - 160 hours at a pH from 6 to 9 in an aqueous culture medium containing an assimilable nitrogen source, an assimilable carbon source and mineral salts, and the isolation in solvent extraction and chromatography, is characterized by the fact that a culture medium is used whose carbon source content is equal to or greater than 10%, and that the culture is carried out by stirring corresponding to an absorbed power of 2 - 4 watts per litres, and with an air flow of from 0.7 to 1 2 liters per liter of medium per minute.

Som carbonkilde kan benyttes stivelse, glucose, dextrin Starch, glucose, dextrin can be used as a carbon source

eller melasse. Som nitrogenkilde kan benyttes maisstopvæske, soya-mel, jordnottmel, kjottekstrakt, pepton, casein eller caseinhydroly-sat. Egnede mineralsalter er kalsiumcarbonat, eller natrium, kali-um, magnesium, jern, kobber, sink, mangan eller koboltklorid. Fos-fatene har ikke funnet anvendelse, da en okning i konsentrasjonen a^ disse i dyrkningsmediet minsker utbyttet av.-de antibiotiske forbindelser. Dyrkningen utfores som nevnt ; ved en temperatur fra 23 til 37°C i 60 til 160. timer ved en pH fra 6 til 9. ■ Dyrkningen kan utfores i en Erlenmeyer-kolbe eller i laboratorie- eller indu^-strielle gjæringskar av varierende stbrrelse. Når dyrkningen er over, kan axenomycin D isoleres fra mycelet, separeres fra gjærings-væsken ved ekstraksjon med et oppløsningsmiddel og renses ved kro-matografi. or molasses. As a nitrogen source, corn starch liquid, soya flour, peanut flour, meat extract, peptone, casein or casein hydrolysate can be used. Suitable mineral salts are calcium carbonate, or sodium, potassium, magnesium, iron, copper, zinc, manganese or cobalt chloride. The phos-fats have not found application, as an increase in the concentration of these in the culture medium reduces the yield of the antibiotic compounds. Cultivation is carried out as mentioned; at a temperature from 23 to 37°C for 60 to 160 hours at a pH from 6 to 9. ■ The cultivation can be carried out in an Erlenmeyer flask or in laboratory or industrial fermentation vessels of varying strength. When the cultivation is over, axenomycin D can be isolated from the mycelium, separated from the fermentation broth by extraction with a solvent and purified by chromatography.

Axenomycin D er opploselig i alkoholer, uopploselig i vann og benzen, og smelter ved 174 - 175°C med spaltning, [a]D 22 = +11 Axenomycin D is soluble in alcohols, insoluble in water and benzene, and melts at 174 - 175°C with cleavage, [a]D 22 = +11

(c = 0,5 methanol); Rf = 0,35 over silicagel (ethylacetat:Isopropanol:vann = 100:35:5). U.V. spektret i methanol har maksimum ved 250, 255 og 330 mu. og en skulder ved 265 - 268 mu-, 138 (c = 0.5 methanol); Rf = 0.35 over silica gel (ethyl acetate:isopropanol:water = 100:35:5). UV the spectrum in methanol has maxima at 250, 255 and 330 mu. and a shoulder at 265 - 268 mu-, 138

(255 mu.) . I .R. spektret viser absorpsjonsbånd ved 3440 , 2980, (255 mu.) . In .R. the spectrum shows absorption bands at 3440 , 2980,

2950, 2890, 1735,. 1705, 1675, 1630, 1610, 1465, 1385, 1355, 1290, 1265, 1195, lY70i 1115,.1080, 1050, 1005, 995, 975, 945, 925, 895, 865, 810, 700 cm<-1>.. Elementæranalyser.viser:C = 60,25 %, 2950, 2890, 1735,. 1705, 1675, 1630, 1610, 1465, 1385, 1355, 1290, 1265, 1195, lY70i 1115,.1080, 1050, 1005, 995, 975, 945, 925, 895, 865, 8010, 1010<7>cm- .. Elemental analyses.show:C = 60.25%,

H = 7,92 0 = 30,35 %. H = 7.92 0 = 30.35%.

De karakteristiske data for de tre antibiotika, The characteristic data for the three antibiotics,

axenomycin A, B og D fremgår av folgende: Axenomycin A, B and D appear from the following:

Det antibiotiske axenomycin D har en hoy antihelmintisk, antiprotozoisk og antifungal aktivitet. Den antihelmintiske aktivitet ble bestemt på mus som var eksperimentelt infisert med Hymeno-lepis nana, i grupper på 10 dyr hver. Axenomycin D ble administrert oralt mellom den 12. og 20.dag efter infeksjon. I tabell 1 er angitt prosent helbredede dyr. The antibiotic axenomycin D has a high antihelminthic, antiprotozoal and antifungal activity. The anthelmintic activity was determined on mice experimentally infected with Hymeno-lepis nana, in groups of 10 animals each. Axenomycin D was administered orally between the 12th and 20th day after infection. Table 1 shows the percentage of cured animals.

Den akutte toksisitet av axenomycin D, uttrykt som LD5Q, i mus er ca. 200 mg/kg ved oral administrasjon. The acute toxicity of axenomycin D, expressed as LD5Q, in mice is approx. 200 mg/kg by oral administration.

TA BELL 2 In vitro anthelmintisk aktivitet av axenomycin A, B og D TA BELL 2 In vitro anthelmintic activity of axenomycin A, B and D

Folgende eksempler illustrerer oppfinnelsen: The following examples illustrate the invention:

Eksempel 1 Example 1

En 2000 ml's kolbe inneholdende 500 cm 3dyrkningsmedium ble sterilisert ved 120°C i 20 minutter. Sammensetningen av dyrkningsmediet for innpodning var: A 2000 ml flask containing 500 cm 3 of culture medium was sterilized at 120°C for 20 minutes. The composition of the culture medium for inoculation was:

Kolben ble innpodet med sporesuspensjon erholdt ved vask-ning av fire 15 dager gamle skrå-agarkulturer av Streptomyces lisandri på' potet-glucose-agar-medium. Kolben ble inkubert ved 25°C i ca. 48 timer i en rotasjonsrister ved 120 omdreininger pr. minutt. 50 ml av denne kultur ble benyttet for å innpode en 5 liters glass-gjæringsbeholder inneholdende 3 liter av et medium med sararac sammensetning som ovenfor. Dyrkningsopplosningen ble omrort ved 500 omdreininger pr. minutt av to turbinplatepropeller med kurvede blad og gjennomluftet med en luftstrom på 0,7 liter pr. liter medium pr. minutt i 24 - 28 timer ved 27 - 23°C. 5 liters glass-gjæringskar, hvert inneholdende 3 liter dyrkningsmedium, ble innpodet med en mengde av forkulturen tilsvarende 5 % av volumet av det produktive medium. Sammensetningen av dyrkningsmediet i den produktive fase i hver av to tester var: The flask was inoculated with spore suspension obtained by washing four 15-day-old slant agar cultures of Streptomyces lysandri on potato-glucose-agar medium. The flask was incubated at 25°C for approx. 48 hours in a rotary shaker at 120 revolutions per minute. 50 ml of this culture was used to inoculate a 5 liter glass fermentation vessel containing 3 liters of a medium with sararac composition as above. The culture solution was stirred at 500 rpm. minute by two turbine plate propellers with curved blades and ventilated with an air flow of 0.7 liters per liter of medium per minute for 24 - 28 hours at 27 - 23°C. 5 liter glass fermentation vessels, each containing 3 liters of culture medium, were inoculated with an amount of the pre-culture corresponding to 5% of the volume of the productive medium. The composition of the culture medium in the productive phase in each of two tests was:

Dyrkningsmediet ble orarort ved 500 omdr./min ved hjelp av to turbinplatepropeller med 6 kurvede blad (absorbert kraft 3,5 watt pr. liter) med en luftstrom på 1 liter pr. liter pr. minutt. Efter 136 timers gjæring ble folgende utbytter erholdt: The culture medium was aerated at 500 rpm using two turbine plate propellers with 6 curved blades (absorbed power 3.5 watts per liter) with an air flow of 1 liter per liters per minute. After 136 hours of fermentation, the following yields were obtained:

Eksempel 2 Example 2

Dyrkningen ble utfort i 5 liters gjæringskar under de samme betingelser som i eksempel 1. Mediet i den produktive fase som inneholdt 12 % glucose, ble benyttet sammen med små mengder kalium-dihydrogenfosfat. Resultatene var: The cultivation was carried out in 5 liter fermentation vessels under the same conditions as in example 1. The medium in the productive phase containing 12% glucose was used together with small amounts of potassium dihydrogen phosphate. The results were:

Eksempel 3 Example 3

Dyrkningen ble utfort i 5 liters gjæringskar som i eksempel 1, med 12 % glucose i mediet til den produktive fase og ved 500 og 650 omdr./min (absorbert kraft 3,5 og 4,0 watt) og med luftstrøm-mer på 1 liter og 1,7 liter pr. liter pr. minutt. Folgende resul-tater ble erholdt: The cultivation was carried out in 5 liter fermentation vessels as in example 1, with 12% glucose in the medium for the productive phase and at 500 and 650 rpm (absorbed power 3.5 and 4.0 watts) and with air flows of 1 liter and 1.7 liters per liters per minute. The following results were obtained:

Eksempel h Example h

Et 80 liter's gjæringskar av rustfritt stål inneholdende An 80 liter fermentation vessel made of stainless steel containing

50 liter forkulturmedium med samme sammensetning som i eksempel 1, ble podet med 500 ml av en kultur erholdt i en 2000 ml's. kolbe som beskrevet i eksempel 1. Etter 2h timer's inkubering i gjærings-kaiet ved omroring og gjennomlufting, ble erholdt en mycelievekst tilstrekkelig til å pode et 500 liter's gjæringskar av rustfritt stål. Dette gjæringskar inneholdt 300 liter av et dyrkningsmedium med folgende sammensetning av den produktive fase: 50 liters of pre-culture medium with the same composition as in example 1 was inoculated with 500 ml of a culture obtained in a 2000 ml's. flask as described in example 1. After 2 hours' incubation in the fermentation dock by stirring and aeration, a mycelial growth sufficient to inoculate a 500 liter stainless steel fermentation vessel was obtained. This fermentation vessel contained 300 liters of a culture medium with the following composition of the productive phase:

Etter 136 timer's inkubering ved 28° C med omroringsbetin-gelser på 250 omdr./minutt av to turbinplatepropeller med 8 flate blader ( absorbert kraft 2,5 watt pr. liter) og gjennomluftning med en luftstrom på 0,7 liter/liter/minutt, med et mottrykk på 1 atmos-fære, ble det erholdt et gjæringsutbytte på 3050 y/ml. Mycelet som ble gjenvunnet ved filtrering av lk liter's kulturkraft, ble ek-strahert to ganger under omroring med h liter butanol hver gang. De kombinerte ekstrakter ble konsentrert til ca. 300 ml. Det erholdte After 136 hours of incubation at 28° C with stirring conditions of 250 rpm by two turbine plate propellers with 8 flat blades (absorbed power 2.5 watts per liter) and aeration with an air flow of 0.7 liters/liter/minute , with a back pressure of 1 atmosphere, a fermentation yield of 3050 y/ml was obtained. The mycelium, which was recovered by filtering 1 liter of culture stock, was extracted twice while stirring with 1 liter of butanol each time. The combined extracts were concentrated to approx. 300 ml. It obtained

bunnfall ble gjenvunnet ved sentrifugering, vasket med diethylether og torket under vakuum. Det derved erholdte urene produkt ble lost i methano1, små mengder uloselig produkt ble fraskilt ved filtrering, og losningen fort gjennom en kolonne av kiselsyre og eluert med ethylacetat :methanol: vann (125: 2'5:17). Under elueringen ble prover av forskjellige fraksjoner analysert ved tynnskiktkromatografi. De forste fraksjoner (ca. 2 liter av eluatet) ble fjernet. De derpå folgende fraksjoner inneholdt axenomycin D som ble gjenvunnet under vakuum ved fordampning av losningsmidlet. Ved krystallisasjon fra methanol-isopropanol ble det erholdt 7 g av produktet. precipitate was recovered by centrifugation, washed with diethyl ether and dried under vacuum. The thus obtained impure product was dissolved in methanol, small amounts of insoluble product were separated by filtration, and the solution passed through a column of silicic acid and eluted with ethyl acetate:methanol:water (125:2'5:17). During the elution, samples of different fractions were analyzed by thin-layer chromatography. The first fractions (about 2 liters of the eluate) were removed. The subsequent fractions contained axenomycin D which was recovered under vacuum by evaporation of the solvent. By crystallization from methanol-isopropanol, 7 g of the product were obtained.

Claims (1)

Fremgangsmåte ved fremstiIling av et antibiotikum, axenomycin D, ved dyrkning av en stamme av Streptomyces lisandri ved en temperatur fra 23 til 37°C i 60 - 160 timer ved en pH fra 6 til 9 i et vandig dyrkningsmedium inneholdende en assimilerbar nitrogenkilde, en assimilerbar carbonkilde og mineralsalter, og isole-ring ved oppldsningsmiddelekstraksjon og kromatografering, karakterisert ved at der anvendes et dyrkningsmedium hvis carbonkildeinnhold er lik eller stdrre enn 10 %, og at dyrkningen utfores ved omroring tilsvarende en absorbert kraft på 2 - 4 watt pr. liter, og med en luftstrom på fra 0,7 til 2 liter pr. liter medium pr. minutt.Process for the preparation of an antibiotic, axenomycin D, by growing a strain of Streptomyces lysandri at a temperature of 23 to 37°C for 60 - 160 hours at a pH of 6 to 9 in an aqueous culture medium containing an assimilable nitrogen source, an assimilable carbon source and mineral salts, and isolation by solvent extraction and chromatography, characterized in that a culture medium is used whose carbon source content is equal to or greater than 10%, and that the culture is carried out by agitation corresponding to an absorbed power of 2 - 4 watts per litres, and with an air flow of from 0.7 to 2 liters per liter of medium per minute.
NO1613/71A 1970-05-04 1971-04-30 NO131549C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT24144/70A IT1044819B (en) 1970-05-04 1970-05-04 ANTIBIOTIC COMPOUND

Publications (2)

Publication Number Publication Date
NO131549B true NO131549B (en) 1975-03-10
NO131549C NO131549C (en) 1975-06-18

Family

ID=11212205

Family Applications (1)

Application Number Title Priority Date Filing Date
NO1613/71A NO131549C (en) 1970-05-04 1971-04-30

Country Status (18)

Country Link
JP (1) JPS5422520B1 (en)
AT (1) AT303256B (en)
BE (1) BE766606R (en)
CA (1) CA981199A (en)
CH (1) CH518360A (en)
CS (1) CS170544B2 (en)
DE (1) DE2121248C3 (en)
DK (1) DK127559B (en)
ES (1) ES390826A2 (en)
FR (1) FR2092128B2 (en)
GB (1) GB1285163A (en)
IE (1) IE36010B1 (en)
IT (1) IT1044819B (en)
NL (1) NL153272B (en)
NO (1) NO131549C (en)
SU (1) SU377991A3 (en)
YU (1) YU35163B (en)
ZA (1) ZA712820B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL153271B (en) * 1968-06-11 1977-05-16 Farmaceutici Italia METHOD FOR PREPARING ANTIBIOTICS USING A STREPTOMYCES ORGANISM AND MEDICINAL PRODUCTS CONTAINING ANTIBIOTICS.

Also Published As

Publication number Publication date
DE2121248B2 (en) 1978-06-22
FR2092128A2 (en) 1972-01-21
YU35163B (en) 1980-09-25
IT1044819B (en) 1980-04-21
NO131549C (en) 1975-06-18
IE36010B1 (en) 1976-07-21
CA981199A (en) 1976-01-06
SU377991A3 (en) 1973-04-17
YU107771A (en) 1980-03-15
AT303256B (en) 1972-11-27
DE2121248C3 (en) 1979-03-15
NL7105286A (en) 1971-11-08
NL153272B (en) 1977-05-16
DE2121248A1 (en) 1971-11-18
IE36010L (en) 1971-11-04
BE766606R (en) 1971-11-03
DK127559B (en) 1973-11-26
ZA712820B (en) 1972-01-26
CH518360A (en) 1972-01-31
GB1285163A (en) 1972-08-09
CS170544B2 (en) 1976-08-27
FR2092128B2 (en) 1974-10-18
ES390826A2 (en) 1973-06-01
JPS5422520B1 (en) 1979-08-07

Similar Documents

Publication Publication Date Title
EP0335386B1 (en) Ks-506 compounds and process for the production thereof
US2789939A (en) Production of glutamic acid by cephalosporium
JPH02124883A (en) Isoflavone derivative having antioxidation activity and production thereof
NO128618B (en)
US4414226A (en) 1,4-Naphtoquinone derivatives and their use in treating coccidiosis
NO143026B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF NEW, THERAPEUTICALLY EFFECTIVE HALOGEN DERIVATIVES
JPS6254433B2 (en)
NO131549B (en)
SU1069631A3 (en) Method for preparing tilactone and strain streptomyces fradiae nrrl 12188 for use in preparing tilactone
US3896002A (en) Production of brefeldin-A
US4497797A (en) β-Galactosidase inhibitor GT-2558 and its derivatives
IL45888A (en) Process for producing deacetoxycephalosporin c
US4155812A (en) Fermentation process for converting L-gulonic acid to 2-keto-L-gulonic acid
NO790319L (en) PROCEDURES FOR MANUFACTURING THE MONORDER
US4013515A (en) Process for the preparation of the antibiotic 20.798 R.P.
FI70595C (en) FRAMSTAELLNINGSFOERFARANDE FOER NARASIN
US3564019A (en) Tetracyclic lactone antifungal agents
EP0284358B1 (en) Novel anti-tumor compounds, method for the preparation thereof, and pharmaceutical preparations containing them
JPH0740950B2 (en) Microbial production of nicotianamine
EP0478064A2 (en) Microbial preparation of 13beta-13-deoxy-22,23-dihydro avermectin-B1a/B1b aglycone
JPH0374677B2 (en)
KR820000295B1 (en) Process for the production of coenzymc q
JP2844214B2 (en) Method for producing 4a-hydroxymilbemycin αs
NO863077L (en) PROCEDURE FOR MICROBIAL HYDROXYLATION OF PRECOLINE AND ITS DERIVATIVES BY NEUROSPORA CRASSA.
SU615652A1 (en) Method for producing optically active (-)2-methyl-5-(1-oxyethyl)pyridine